Cash Balance: Ended the year with $754 million in cash. Operating Expenses: 35% reduction in pro forma operating expenses year over year. 2026 Cash Operating Expenses: Expected to be under $390 ...

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...

Recursion Pharmaceuticals’s stock price closed at $3.53. It is down -23.76% in the last 3 months and down -57.67% in the last 12 months. Recursion Pharmaceuticals saw 3 positive EPS revisions and 1 ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple ...

Najat Khan: Good morning, and thank you so much for joining us. I want to start by briefly framing where Recursion Pharmaceuticals, Inc. is today in its journey and evolution. Over the past decade, ...

Apheris, a Berlin-based company focused on enabling governed, private, and secure access to data for machine learning, has announced the launch of the ADMET Network, a federated initiative that allows ...

Abstract: In high-performance processor design, maintaining Return-Address Stack (RAS) integrity is crucial for efficient instruction flow. Yet, separating multi-level branch predictors from ...